The stock will trade on the mid-2026 IND filing and RESCUE program start, not on Q1 financials. The $234M cash runway through 2029 removes near-term financing risk. Watch for the IND filing announcement and initial 3-month Phase 3 data expected by YE 2026 as the next catalysts.
RLMD drugs
RLMD drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · May 13 $7.49entry
- T+1 · 6mo ago 0.00%α +0.00% · $7.49
- T+5 · 6mo ago −6.14%α −4.98% · $7.03
- T+20 · 5mo ago −12.95%α −12.34% · $6.52
- T+60 · 3mo ago −34.05%α −38.48% · $4.94
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Relmada Therapeutics reported Q1 2026 results that were in line with its pre-revenue clinical-stage profile, with a net loss of $19.1M ($0.22/share) vs. consensus of $-0.20. The key event is the reiteration of mid-2026 timelines to file the NDV-01 IND and initiate the Phase 3 RESCUE registrational program, supported by a $234M cash balance (post $160M PIPE) funding operations through 2029. The filing is neutral, no financial beat or miss, no guidance change, and the clinical milestones were already telegraphed in the prior quarter's update.
Key Financial Metrics
Key Facts
- Q1 2026 net loss of $19.1M ($0.22/share) vs. consensus $-0.20, a 12.8% miss on EPS
- Cash, cash equivalents, and short-term investments of $234.0M as of March 31, 2026, including ~$150M net from March 2026 PIPE
- On track to file NDV-01 IND and initiate Phase 3 RESCUE program in mid-2026
- Filed provisional patent application for NDV-01 in April 2026, with potential protection until 2047
- 104.9M shares outstanding as of May 7, 2026, up from 73.3M at year-end 2025 due to PIPE issuance
- No revenue reported, clinical-stage biotech with no approved products
Financial Impact
No revenue; net loss $19.1M in Q1 2026 vs. $17.6M in Q1 2025; cash burn $15.1M in operating cash flow
Risk Factors
- Phase 3 RESCUE program may fail to replicate Phase 2 efficacy or safety results
- Dilution risk: 104.9M shares outstanding, up from 30.2M at Dec 2024, with additional options/warrants outstanding
- No approved products or revenue; entirely dependent on clinical trial success
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001213900-26-055164 |
| Document: ea029041401ex99-2.htm | 0001213900-26-055164 |
| Document: ea0290414-8k_relmada.htm | 0001213900-26-055164 |
| Document: 0001213900-26-055164-index-headers.html | 0001213900-26-055164 |
| Document: 0001213900-26-055164-index.html | 0001213900-26-055164 |
| Document: 0001213900-26-055164.txt | 0001213900-26-055164 |
| 8-K Data (Synthetic) | 0001213900-26-055164 |
Track record
11 reports on RLMD
2 of 3 bullish or bearish reports moved the stock their way by T+20. Best: +38.81% at T+60 after the May 13, 2026 report. 2 of 3 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Bearish 5/10 Entry $3.54 Now $3.61 −1.98% settles Dec 15
- Nov 16, 2026today 8-K Neutral 3/10 Entry $4.16 Now $3.61 −13.23% settles Dec 15
- Nov 12, 20264d ago 8-K Neutral 4/10 Entry $4.21 Now $3.61 −14.25% settles Dec 14
- Sep 11, 20269w ago Insider Cluster Bullish 6/10 Entry $4.52 to $3.39 Now $3.61 −20.13% ▼ −25.00% −26.87% vs SPY
- May 13, 202626w ago S-3ASR Bearish 6/10 Entry $7.42 to $6.65 Now $3.61 +51.35% ▲ +10.38% +9.52% vs SPY
- May 12, 202626w ago 8-K Neutral 4/10 Viewing Entry $7.49 to $6.52 Now $3.61 −51.80% ▼ −12.95% −12.34% vs SPY
- Apr 17, 202630w ago DEFA14A Neutral 3/10 Entry $7.37 to $6.34 Now $3.61 −51.02% ▼ −13.98% −18.18% vs SPY
- Apr 3, 202632w ago S-3 Neutral 3/10 Entry $6.90 to $7.41 Now $3.61 −47.68% ▲ +7.39% −1.59% vs SPY
- Mar 19, 202634w ago Press Release Bullish 8/10 Entry $6.07 to $7.37 Now $3.61 −40.53% ▲ +21.42% +12.10% vs SPY
- Mar 12, 202635w ago Press Release Neutral 3/10 Entry $6.15 to $7.29 Now $3.61 −41.30% ▲ +18.54% +16.56% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers